Marcyrl Pharmaceutical Industries

Belkins
Marcyrl was established since 1998 as a simple private company “Marcyrl Import & Export Company”. On Jan 17, 2002 and according to Law no. 491 /2002, Marcyrl has received Ministry of health approval to build the factory. Marcyrl is committed to discover, research, develop and manufacture recently generic products and acquire new products to be manufactured under license from Multinational Companies at our facility.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DIAGNOSTICS

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

news image

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

news image

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

news image

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More
news image

DIAGNOSTICS

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

news image

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More
news image

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More
news image

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us